Drug Approval | November 08, 2022
Zydus receives EIR with VAI from USFDA for Moraiya facility
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Monetary awards worth Rs 1.20 crore were presented amongst the winners for their remarkable contributions
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
Subscribe To Our Newsletter & Stay Updated
